GENTIAN ACHIEVES PROOF OF CONCEPT ON FECAL PANCREATIC ELASTASE
22. Jun 2018 |
2 min read
GENTIAN DIAGNOSTICS AS HAS OBTAINED PROOF OF CONCEPT FOR A NEW PRODUCT FOR EXOCRINE PANCREATIC INSUFICIENCY AND MONITORING OF PANCREATIC FUNCTION
Gentian Diagnostics (OSE: GENT-ME) is pleased to announce that it has achieved proof of concept on turbidimetric measurement of Fecal Pancreatic Elastase (fPELA). The project was initiated in November 2017 in collaboration with Gentian's established partner BÜHLMANN Laboratories AG in Basel. The test to be developed from this concept is a measure of Pancreatic Exocrine Insufficiency (PEI) associated with various health conditions, e.g. chronic pancreatitis, cystic fibrosis, celiac disease, diabetes, post-pancreatic surgery, gastrectomy etc.
fPELA testing today is only commercially available on ELISA platforms, and testing is likely to increase if available on highly automated, high throughput chemistry analyzers. If successful, Gentian and its partner BÜHLMANN estimates that the annual test volume could reach 5 to 10 Mio tests annually ex USA.